4Tsang EWK,Yip PSL,Toh MH. The impact of R&D on value added for do- mestic and foreign firms in a newly industrialized economy[J]. Interna- tional Business Review, 2008,17 (4) : 423 - 441. 被引量：1
5Guan JC, Yam RCM, Tang EPY, et al. Innovation strategy and performance during economic transition: evidences in Beijing, China [ J ]. Research Policy, 2009,38(5) :802 - 812. 被引量：1
6Walwyn D. Finland and the mobile phone industry : A case study of the re- turn on investment from government -funded research and development [J]. Technovation, 2007,27 (6 - 7) : 335 - 341. 被引量：1
7Todo Y, Shimizutani S. R & D intensity for innovative and adaptive pur- poses in overseas subsidiaries : Evidence from Japanese multinational en- terprises[J]. Research in International Business and Finnance, 2009,23 (1):31 -45. 被引量：1
8Lin BW, Lee YK, Hung SC. R&D intensity and commercialization orienta- tion effects on financial performance [J]. Journal of Business Research, 2006,59 (6) : 679 - 685. 被引量：1
9Lu LYY, Yang C. The R& D and marketing cooperation across new product development stages:An empirical study of Taiwan's IT industry[J]. Indus- trial Marketing Management, 2004,33 (7) : 593 - 605. 被引量：1
10Leenders MAAM, Wierenga B. The effect of the marketing - R&D interface on new product performance:The critical role of resources and scope [J]. International Journal of Research in Marketing, 2008,25 ( 1 ) : 56 - 68. 被引量：1
二级参考文献13
1EFPIA (The European Federation of Pharmaceutical Industries and Associations).The pharmaceutical industry in figures[R].Brussels:2006. 被引量：1
2Tufts Center for the Study of Drug Development.Post-approval R&D raises total drug development costs to $ 897 million[R].Boston:2003. 被引量：1
3DIMASI J,RONALD H,HENRY G.The price of innovation:new estimates of drug development costs[J].J Health Econ,2003,22(2):151-185. 被引量：1
4PhRMA.2004 Industry profile[R].Washington DC:2005. 被引量：1
5Tufts Center for the Study of Drug Development.Therapeutic class is a critical determinant of drug development cost and time[R].Boston:2004. 被引量：1
6DANZON P,SEAN N,NUNO P.Productivity in pharmaceutical-biotechnology R&D:The role of experience and alliance[R].NBER Working Paper 9615,April 2003. 被引量：1
7Charles River Associates.Innovation in the pharmaceutical sector[R].London:November 2004. 被引量：1
8FDA.Innovation or Stagnation:Challenge and opportunity on the critical path to new medical products[R].Rockville:March 2004. 被引量：1
9The Association of American Medical Colleges,Food and Drug Administration,Center for Drug Development Science at the University of California San Francisco,Drug Development Science.Obstacles and opportunities for collaboration among academia,industry and government[R].January 2005. 被引量：1
10Lehman Brothers.Assessing the current and future impact of genomics on R&D costs,complexity,and success rates[R].2001. 被引量：1
